Epidarex Capital is a transatlantic venture firm focused on building early-stage life science and health technology companies in emerging research hubs. They concentrate on under-ventured markets in the UK and the US, identifying world-class science and innovation to create high-growth businesses. Their unique approach involves acting as a founding or early investor, actively building companies to translate promising academic research into commercially successful enterprises.